Member Info for sphinx100

I meant to say 3.2 million buy at the close !!

Another 3 million plus under the radar , does make you think someone wants these under .7p

I see they are doing their own research into “Gut microbiota” doesn’t include ff so far as I can tell .

Interesting that Life space revenue was 2.8 billion yuan incredible growth in just a few years !

I wonder if HMOs have ff in them ! The research study is at the bottom of this page . https://www.dsm.com/human-nutrition/en/products/hmos/hmos-for-gut-health.html

Doesn’t look like SL or DSM have reduced their holding ! Updated 21st July ....https://www.provexis.com/shareholder-information/major-shareholders/

Maybe it’s part of this . ..https://www.dsm.com/corporate/searchresults.html?query=Fruitflow+microbiota&pageNum=1&languageCode=en&siteName=corporate&filtersRequired=pageKeyWords

Bodes well for pxs if we can get some products launched in China , I can’t get onto the By health site either

It seems that pxs share of the AA agreement could have been as low as 5% , which makes taking over production even more of a no brainer ! Imho

An agreement was signed with Firmenich in July 2022 to optimise scale up and development of another type of SweetBiotix®. They will pay OptiBiotix a six figure payment per market approval (USA/Europe/Asia) plus royalties and additional milestones on sales. As previously disclosed, Firmenich are one of the world leaders in taste and the world's largest stevia supplier. Their turnover is around £3.6bn per year which has risen to US $11.4bn annual turnover following their merger with DSM, and are now known as DSM Firmenich. They are experts in their field and chose SweetBiotix® after an 18 month due diligence process. This agreement with one of the leaders in the field after extensive due diligence of the science, taste, and intellectual property, is a substantial validation of the SweetBiotix® science and commercial potential.

Our products are also tested by different academic groups providing an independent assessment of their taste and prebiotic functionality. The most recent peer reviewed publication (see Prebiotic Potential of a New Sweetener Based on Galactooligosaccharides and Modified Mogrosides - PubMed (nih.gov)) in a respected industry journal concluded 'These substrates could be considered as novel candidate prebiotic sweeteners, foreseeing a feasible and innovative approach targeting the sucrose content reduction in food. This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fibre functionality'.This is interesting and frustrating that they treated this company (opti) so much better than they have treated pxs , but note they only paid opti 5% of profit ,but a large upfront payment of 6 figures .

Https://www.infotelligent.com/company/nao-medical/142070498

Something on nao. https://naomedical.com/careers/

There was also 3.5 m bought yesterday , so about 10 m total , as usual we can only guess what’s going on !

Nice after bell buy @.72 , 6778255 , someone’s confident !

And an important foothold in the states!

From the interims “The Company is seeking to expand further its commercial activities with Fruitflow+ Omega-3 and other Fruitflow+ combination products, and it is currently in dialogue with some other potential international direct selling customers.”

Great find gixer one of the existing 50 customers or a new one !

And much more important , what has happened with all the carrots dangled over the last 6 or 7 years !

Only another 10 weeks until full year results will be released , unless news comes earlier , those will clarify what DSM were doing all those years although only 2 months of full inCome will be shown , only expecting £500k t/o although would be happy to be proved wrong .

How loss-making companies receive their R&D credit

If you are a loss-making company how you will receive the SME R&D tax credit will also be affected. Whereas profit-making companies receive a deduction from their Corporation Tax bill, loss-making companies can receive a partial or full cash-credit for their R&D expenditure.

Alternatively, loss-making companies can choose to carry forward their losses to a future profitable year. This may make sense if your future profitability is predictable, as the return can be higher than if you receive a cash credit, however for most loss-making companies the immediate cash credit is preferred. Returns from carried forward losses can reach 20% of the enhanced R&D expenditure, whereas the cash credit is delivered at a rate of 14.5%. Choosing to take the immediate cash credit, rather than carrying the loss onto your future tax bill is called “Surrendering the Loss“.

For more information about how your R&D tax credit is calculated we recommend looking over our guide to how much you can claim. Otherwise, get in touch with one of our team and they will be able to advise you free of charge.